Revolution Medicines

US · RVMD #499 by market cap Listed 2020

200.87 +1.00 +0.50%

Live - 5344 symbols - heartbeat 373s ago · 2026-10-08 06:00

Pre-market 199.75 -0.56%

After-hours 199.81 -0.53%

Overnight 199.95 -0.46%

Market cap: 43.05B
P/E (TTM): -22.65
P/B: 16.52
EPS: -5.95
Div yield: 0.00%
52W pos: 87%

Reader sentiment Are you bullish or bearish on RVMD?

Anonymous reader poll. Unscientific, not investment advice.

About Revolution Medicines

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Founded: 2004
CEO: Dr. Mark A. Goldsmith, M.D., PhD
Employees: 883
Headquarters: Redwood City, California, United States of America
Fiscal year end: 12-31
Website: revmed.com

Company profile

Exchange: US
Symbol: RVMD
Market-cap rank: #499
Listing date: 2020-02-13
Market cap: 43.05B
Float cap: 37.08B
Shares out: 214.34M
Float shares: 184.61M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 06:00:04 · For reference only, not investment advice and not tailored to your situation.